CAPLYTA Q1 2024 net product sales were $144.8 million, compared to$94.7 million for the same period in 2023, representing a 53% increase CAPLYTA's strong prescription uptake continues: Q1 2024 CAPLYTA total prescriptions increased 39%, versus the same period in 2023 CAPLYTA 2024 net product sales guidance reiterated at $645 -$675 million Announced robust positive Phase 3 results from Study 501 evaluating lumateperone as an adjunctive therapy to antidepressants in patients with major depressive disorder (M ...